Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SCN4A | P35499 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6914407 | 0.74 | MAPT (0.43) | GAAALDH1A1KDM4EHTTNPSR1 | |
| SCHEMBL1691570 | 0.70 | ALDH1A1 (0.39) | GAAALDH1A1KDM4EHTTNPSR1 | |
| SCHEMBL3709748 | 0.69 | HTR2C (0.55) | GAAALDH1A1KDM4EHTTNPSR1 | |
| SCHEMBL3222750 | 0.68 | MAPT (0.41) | GAAALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL29467814 | 0.67 | KDM4E (0.47) | GAAALDH1A1KDM4EHTTTSHR | |
| SCHEMBL30757835 | 0.66 | GAA (0.46) | GAAALDH1A1KDM4EHTTSCN5A | |
| SCHEMBL15007392 | 0.66 | AVPR1A (0.53) | GAAALDH1A1KDM4EHTTNPSR1 | |
| SCHEMBL7943022 | 0.65 | NOS2 (0.48) | GAAALDH1A1KDM4EHTTOPRD1 | |
| SCHEMBL14813582 | 0.65 | ALDH1A1 (0.42) | GAAALDH1A1KDM4EHTTNPSR1 | |
| SCHEMBL29291524 | 0.65 | MAPT (0.37) | GAAALDH1A1KDM4ELMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4562010-A1 | CRYSTALLINE FORMS OF AN AKR1C3 DEPENDENT KARS INHIBITOR | Novartis AG (CH) | 2025-06-04 | — | — | EP | claimed |
| EP-4561702-A1 | METHODS OF TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITOR DOSING FIELD OF THE INVENTION | Novartis AG (CH) | 2025-06-04 | — | — | EP | claimed |
| WO-2024023666-A1 | CRYSTALLINE FORMS OF AN AKR1C3 DEPENDENT KARS INHIBITOR | NOVARTIS AG (CH) | 2024-02-01 | — | — | WO | claimed |
| WO-2024023641-A1 | METHODS OF TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITOR DOSING FIELD OF THE INVENTION | NOVARTIS AG (CH) | 2024-02-01 | — | — | WO | claimed |
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4562010-A1 | CRYSTALLINE FORMS OF AN AKR1C3 DEPENDENT KARS INHIBITOR | Novartis AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| EP-4561702-A1 | METHODS OF TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITOR DOSING FIELD OF THE INVENTION | Novartis AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| CN-114206870-B | Tricyclic AKR1C 3-dependent KARS inhibitors | 诺华股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240262827-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-08-08 | — | — | US | disclosed |
| EP-4349839-A2 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024023666-A1 | CRYSTALLINE FORMS OF AN AKR1C3 DEPENDENT KARS INHIBITOR | NOVARTIS AG (CH) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024023641-A1 | METHODS OF TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITOR DOSING FIELD OF THE INVENTION | NOVARTIS AG (CH) | 2024-02-01 | — | — | WO | disclosed |
| EP-4013500-B1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS AG (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20220315582-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4013500-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| CN-114206870-A | Tricyclic AKR1C3 dependent KARS inhibitors | 诺华股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315582-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | GAA 541/4885ALDH1A1 234/4885KDM4E 1460/4885 |
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | GAA 541/4885ALDH1A1 234/4885KDM4E 1460/4885 |
| US-20240262827-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | GAA 541/4885ALDH1A1 234/4885KDM4E 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.